Research programme: prostaglandin EP4 receptor antagonists - RaQualia PharmaAlternative Names: RQ-00000008
Latest Information Update: 31 Oct 2014
At a glance
- Originator Pfizer
- Developer RaQualia Pharma
- Mechanism of Action Prostaglandin E EP4 receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Acute pain; Autoimmune disorders; Cancer; Hypersensitivity; Inflammation; Inflammatory pain